Alzheimer's treatment

Master Formulation Record

The TRAILBLAZER-ALZ 2 study (NCT04437511) demonstrated significant clinical benefits of donanemab-azbt in early symptomatic Alzheimer disease (AD). Here are the key findings:Efficacy OutcomesCognitive & Functional....

To minimize adverse reactions when administering Donanemab-azbt (Kisunla), follow these evidence-based protocols:Pre-Infusion PreparationBaseline Assessments:Perform APOE ε4 genotyping (higher ARIA risk in homozygotes).Obtain a brain MRI....

Drug Information